These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1047 related articles for article (PubMed ID: 30132304)

  • 1. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
    Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial interventions for preventing and treating depression in dialysis patients.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Rabindranath KS; Strippoli GF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004542. PubMed ID: 31789430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet agents for chronic kidney disease.
    Natale P; Palmer SC; Saglimbene VM; Ruospo M; Razavian M; Craig JC; Jardine MJ; Webster AC; Strippoli GF
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD008834. PubMed ID: 35224730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low protein diets for non-diabetic adults with chronic kidney disease.
    Hahn D; Hodson EM; Fouque D
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
    O'Lone EL; Hodson EM; Nistor I; Bolignano D; Webster AC; Craig JC
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD007857. PubMed ID: 30790278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low protein diets for non-diabetic adults with chronic kidney disease.
    Hahn D; Hodson EM; Fouque D
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
    Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
    Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for preventing bone disease in kidney transplant recipients.
    Palmer SC; Chung EY; McGregor DO; Bachmann F; Strippoli GF
    Cochrane Database Syst Rev; 2019 Oct; 10(10):CD005015. PubMed ID: 31637698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
    Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home versus in-centre haemodialysis for people with kidney failure.
    Cheetham MS; Ethier I; Krishnasamy R; Cho Y; Palmer SC; Johnson DW; Craig JC; Stroumza P; Frantzen L; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2024 Apr; 4(4):CD009535. PubMed ID: 38588450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
    Hara T; Hijikata Y; Matsubara Y; Watanabe N
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.